mdgroup, through its patientprimary service, has partnered with Illingworth Research Group, to offer clients an enhanced, patient-centric service.
Studies have found minimizing trips to hospitals, while maintaining a high level of involvement, can be a crucial element to patient recruitment and retention levels, which could ultimately save pharmaceutical and biotech companies millions. This can also have a positive impact on other areas of the study, as allowing patients the choice to have visits performed at home or in the workplace or hybrid solutions reduces the burden on sites.
Through the partnership, patients are offered a choice over the location of many of their clinical trial visits as well as a top class concierge service for travel when clinic visits are necessary, tailoring the service to suit individual needs.
patientprimary is mdgroup’s bespoke patient support service, putting patients at the center of clinical trials. Patientprimary provides the personal touch sometimes lacking from the clinical process. A range of services are available, including patient travel, on-site support and coordination, rapid reimbursement, easy-to-use apps to streamline processes, and now, via Illingworth Research, pre-organized off-site research nurse care.
Illingworth Research Group provides both on-site and mobile research nursing services in a variety of countries worldwide. All nurses are insured and experienced in clinical trials and in completing study visits within patients’ homes, at school or in the workplace.
John Illingworth, chief executive officer of Illingworth Research, said, “This agreement will provide combined value to support clinical trials where patient recruitment and retention is key. This will benefit those clients working in complex, orphan indications and chronic illnesses as well as many others. Where patients decide not to take up mobile visits, the use of the services available through md group’s patientprimary service will ensure their needs are always put first and inconvenience minimized.”
Tarquin Scadding-Hunt, mdgroup’s chief executive officer, said, “This landmark agreement with one of our industry partners will continue to extend our quality services and further assist mdgroup to provide better quality and diversity of care to our patient communities. Reducing the impact that taking part in a clinical trial has on a patient’s family life has been proven to increase adherence and minimise drop-outs.”
